Gapping up
In reaction to earnings/guidance:
- GENI +13.4%, TUYA +8.7%, TITN +4.7%, DY +3.6%, ARWR +3.1%, XPEV +3%, SJM +2.8%, DKS +1.6%, J +1%
Other news:
- AADI +27.5% (FDA approval of its first product FYARRO for patients with locally advanced unresectable or metastatic malignant perivascular epithelioid cell tumor)
- SITM +5.9% (to join S&P MidCap 400)
- EBS +4.5% (moving to the S&P SmallCap 600, leaving the S&P MidCap 400)
- ARWR +3.1% (ARWR enters into license agreement with GSK under which GSK will develop/commercialize ARO-HSD; Arrowhead to receive upfront payment of $120 mln; ARWR also report earnings)
- AVB +1.6% (names new CEO)
- UFPI +0.9% (acquires controlling interest in Ficus Pax for $13.5 mln)
- INDI +0.9% (stock offering)
- HRL +0.8% (increases dividend)
Analyst comments:
- BGRY +7.5% (upgraded to Outperform from Neutral at Credit Suisse)
- BMBL +3.8% (upgraded to Outperform from In-line at Evercore ISI)
- EPAM +1.8% (upgraded to Buy from Hold at VTB Capital)
- ABBV +0.9% (upgraded to Buy from Hold at Societe Generale)